Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Embryonal Neoplasm Clear all
Terminated Phase 2 Interventional Results available

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

NCT01696045
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

NCT03304639
View directory record Official record
Conditions
Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
Pembrolizumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
254
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00869401
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
dasatinib, temozolomide, placebo, radiation therapy
Drug · Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
207
States / cities
Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 20, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

NCT03405792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, WHO Grade IV
Interventions
Temozolomide (TMZ), Optune System, Pembrolizumab
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 20, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

NCT02800486
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma, Brain Neoplasm, Brain Cancer, Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Malignant
Interventions
Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 10:45 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

NCT03906331
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
U.S. locations
34
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 20, 2026, 10:45 AM EDT
Terminated No phase listed Observational

Genetic Study of Brain Tumors in Young Children

NCT00010101
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 3 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

NCT02962167
View directory record Official record
Conditions
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
Interventions
Modified Measles Virus, Modified Measles Virus Lumbar Puncture
Biological
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
12 Months to 39 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas

NCT00766467
View directory record Official record
Conditions
Malignant Glioma
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Eudocia Quant Lee, MD
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

NCT00995007
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions
ZD6474 (Vandetanib), Carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

NCT00609011
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
MPC-6827 + Temozolomide
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Ocoee, Florida • Greenville, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of [225Ac]-FPI-1434 Injection

NCT03746431
View directory record Official record
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide

NCT01478854
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Radiation, Chemotherapy
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

CC-5013 in Treating Patients With Recurrent Glioma

NCT00036894
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

NCT01252251
View directory record Official record
Conditions
Uveal Melanoma
Interventions
RAD001 (Everolimus) and Pasireotide (SOM230) LAR
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

NCT00859222
View directory record Official record
Conditions
Malignant Glioma
Interventions
LBH589, bevacizumab
Drug
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 20, 2026, 10:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

NCT04910022
View directory record Official record
Conditions
Glioblastoma, Diffuse Glioma
Interventions
NMS-03305293, Temozolomide
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
11
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 20, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Education for Prevention of Melanoma in Hispanic Populations

NCT05388851
View directory record Official record
Conditions
Melanoma
Interventions
Educational Intervention, Questionnaire Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 20, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

A Natural History Study of Children and Adults With Olfactory Neuroblastoma

NCT04755205
View directory record Official record
Conditions
Olfactory Neuroblastoma, Esthesioneuroblastoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 120 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Evaluating Therapeutic Response to Novo-TTF

NCT02441322
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Novo-TTF
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 20, 2026, 10:45 AM EDT
Completed No phase listed Observational

Brain Tumor Intraoperative Ultrasound Database

NCT05062772
View directory record Official record
Conditions
Brain Tumor, Brain Neoplasms, Brain Cancer, Glioma, Glioblastoma
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Hospital del Rio Hortega
Other
Eligibility
15 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 20, 2026, 10:45 AM EDT
Completed Early Phase 1 Interventional

Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas

NCT00795457
View directory record Official record
Conditions
Astrocytoma, Oligo-Astrocytoma, Glioma
Interventions
GAA/TT-peptide vaccine and poly-ICLC
Biological
Lead sponsor
Ian F. Pollack, M.D.
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 20, 2026, 10:45 AM EDT